Products
Bexmarilimab Biosimilar Monoclonal Antibody (STAB1) for Research
Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-066-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody |
| INN Name | Bexmarilimab |
| Target | STAB1 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Faron Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis |
| Conditions Discontinued | na |
| Development Tech | na |
About target - STAB1
1. Protein Stabilin-1
2. Gene STAB1
3. Organism Homo sapiens (Human)
Function
Acts as a scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. When inhibited in endothelial tube formation assays, there is a marked decrease in cell-cell interactions, suggesting a role in angiogenesis. Involved in the delivery of newly synthesized CHID1/SI-CLP from the biosynthetic compartment to the endosomal/lysosomal system.
